Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 1, 2002Diabetes CareOpen Access

Hypertriglyceridemic HyperapoB in Type 2 Diabetes

View Full Paper
Ask AI
Bookmark
Share

Authors

Allan D. Sniderman
Allan D. SnidermanMedical Council of CanadaBLBenoı̂t LamarcheUniversité LavalJTJessica TilleyMedical Council of Canada

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Sniderman et al. (2002) studied this question.

synapsesocial.com/papers/6a70e3d4e36a167817e2b79chttps://doi.org/10.2337/diacare.25.3.579
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Apolipoprotein Concentrations During Treatment and Recurrent Coronary Artery Disease Events2000 · 154 citations
  2. 2Atherogenic lipoprotein phenotype in Type 2 diabetes: reversal with micronised fenofibrate1999 · 74 citations
  3. 3Apolipoprotein(B) identifies dyslipidemic phenotypes associated with cardiovascular risk in normocholesterolemic type 2 diabetic patients.1999 · 70 citations
  4. 4Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative Ultracentrifuge1972 · 32,638 citations
  5. 5Relation Between Baseline and On-Treatment Lipid Parameters and First Acute Major Coronary Events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)2000 · 569 citations